# A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

> **NCT01770223** · PHASE4 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** boceprevir
- **BIOLOGICAL:** PegIFN-2b
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01770223
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-01
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01770223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01770223, "A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01770223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*